Inaugural ADC Linker & Conjugation Summit
Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index.
The inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs, with low aggregation and controlled release, which can be replicated at scale.
See the complete event guide here.
Here’s a snapshot of our speaker faculty, including expert industry leaders such as:
- Sayumi Yamazoe, Senior Principal Scientist, Bristol Myers Squibb
- Romas Kudirka, Director, Chemistry & Bioconjugation, Bolt Biotherapeutics
- Donglu Zhang, Senior Fellow, Genentech
- Paul Song, Chief Scientific Officer, Genequantum
- Patrick Higgs, Principal Scientist, Chemistry, Iksuda
- Noah Bindman, Principal Scientist, Seagen
- Marc-André Kasper, Director, Chemistry & Early Discovery, Tubulis
- Paul Sauter, Director, Chemistry, VERAXA
…and many more!
Find the full list of speakers and session details here.
Be part of the first industry-dedicated meeting for professionals just like you, interested in learning about developments in the field of ADC linkers and conjugations, and overcoming common challenges with stability, control payload release and reducing off-target toxicities, as well as learning from key development and manufacturing considerations.
